Overview
Autoimmune neuritis affecting nerve roots and/or plexuses encompasses a spectrum of inflammatory conditions characterized by immune-mediated damage to peripheral nerves. These conditions often manifest as chronic pain, motor deficits, and sensory disturbances, significantly impacting patients' quality of life. The pathophysiology involves complex interactions between immune cells, particularly macrophages and lymphocytes, and neural tissues, leading to inflammation and nerve dysfunction. Emerging evidence highlights the role of specific immune mediators and potential therapeutic targets, such as macrophage polarization states, neural cell adhesion molecules, and stem cell therapies, which offer promising avenues for treatment and management.
Pathophysiology
The underlying mechanisms of autoimmune neuritis involve intricate bidirectional crosstalk between pain and inflammation, primarily mediated by macrophage polarization states. M1 macrophages, known for their pro-inflammatory profile, activate and secrete cytokines such as IL-2, IFN-γ, and TNF-α, which exacerbate chronic inflammatory processes characteristic of autoimmune neuritis [PMID:37108462]. This pro-inflammatory milieu not only amplifies local tissue damage but also perpetuates neuropathic pain, creating a vicious cycle that is challenging to interrupt clinically.
Conversely, the involvement of bone marrow-derived mesenchymal stem cells (BM-MSCs) provides a counterbalancing mechanism. Studies have demonstrated that BM-MSCs effectively reduce the infiltration of inflammatory cells, including CD4+ and CD8+ T cells and CD68+ macrophages, while simultaneously decreasing levels of pro-inflammatory cytokines like IL-2, IFN-γ, and TNF-α [PMID:24935408]. Importantly, BM-MSCs enhance anti-inflammatory responses by upregulating IL-10, a cytokine known for its immunosuppressive properties. This dual action suggests that BM-MSCs could serve as a therapeutic agent to mitigate the inflammatory cascade and promote neuroprotection in autoimmune neuritis.
Further insights into the immune-mediated mechanisms come from the role of neural cell adhesion molecules (NCAMs). Anti-NCAM antibodies interfere with the direct adhesion between lymphocytes and sensory neurons, a process that is opioid-dependent [PMID:17122239]. This interaction underscores the critical role of immune cell-neuron interactions in perpetuating nerve root and plexus inflammation. Disrupting these interactions through targeted therapies, such as blocking NCAM, could potentially alleviate symptoms and halt disease progression in autoimmune neuritis.
Diagnosis
Diagnosing autoimmune neuritis involves a comprehensive clinical evaluation complemented by specific diagnostic tests. Clinicians typically observe patients presenting with asymmetric sensory and motor deficits, often accompanied by pain that may be neuropathic in nature. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), are crucial for identifying demyelination or axonal damage characteristic of nerve root and plexus involvement. Cerebrospinal fluid (CSF) analysis may reveal elevated protein levels with normal or slightly elevated cell counts, indicative of a mild inflammatory process. Serological testing for autoantibodies, particularly those targeting neural antigens like NCAM, can provide supportive evidence for an autoimmune etiology, although these tests may not be universally positive in all cases. Imaging studies, such as MRI, can help visualize structural changes in nerve roots and plexuses, further aiding in diagnosis.
In clinical practice, the diagnostic approach often requires integrating clinical symptoms with objective findings from multiple modalities to rule out other causes of peripheral neuropathy, such as metabolic disorders, infections, or compressive lesions. The heterogeneity of autoimmune neuritis necessitates a tailored diagnostic strategy that considers individual patient presentations and clinical context.
Management
Pharmacological Approaches
While specific pharmacological treatments tailored to autoimmune neuritis are limited, managing the inflammatory component remains a cornerstone of therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids can provide symptomatic relief by reducing inflammation and pain. However, their long-term efficacy and potential side effects necessitate careful monitoring. Immunosuppressive agents, such as methotrexate or intravenous immunoglobulin (IVIG), may be considered in severe cases to modulate the immune response, although evidence specific to autoimmune neuritis is still evolving.
Emerging Therapies
#### Mesenchymal Stem Cells (MSCs)
The therapeutic potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) is increasingly recognized in autoimmune neuritis. Studies indicate that BM-MSCs not only reduce the infiltration of inflammatory cells like CD4+ and CD8+ T cells and CD68+ macrophages but also modulate cytokine profiles, decreasing pro-inflammatory cytokines (IL-2, IFN-γ, TNF-α) and enhancing anti-inflammatory responses (IL-10) [PMID:24935408]. Clinical trials combining BM-MSCs with other therapeutic modalities, such as engineered axon guidance conduits (xANGs), have shown promising outcomes, including improved nerve repair function and reduced inflammatory reactions, as evidenced by enhanced walking-track tests and electrophysiological improvements [PMID:24935408]. These findings suggest that MSC therapy could be a valuable adjunct in managing the inflammatory aspects of autoimmune neuritis.
#### Targeting Macrophage Polarization
Targeting macrophage polarization states offers another innovative therapeutic approach. Hyaluronic acid-based nanosystems designed to interact with CD44 receptors on macrophages have demonstrated significant anti-inflammatory and antinociceptive effects [PMID:37108462]. By shifting macrophage polarization towards an M2 phenotype, which is more anti-inflammatory, these nanosystems could potentially mitigate the chronic inflammatory burden seen in autoimmune neuritis. This approach holds promise for reducing both inflammation and associated neuropathic pain, though further clinical validation is needed.
Immune Modulation
Blocking specific immune interactions, such as those mediated by NCAM, represents a novel therapeutic strategy. Anti-NCAM antibodies interfere with the adhesion between lymphocytes and sensory neurons, potentially disrupting key inflammatory pathways [PMID:17122239]. While still in the experimental phase, therapies targeting NCAM could offer a targeted way to disrupt immune cell interactions with neural tissues, thereby alleviating symptoms and slowing disease progression in autoimmune neuritis.
Key Recommendations
By integrating these recommendations, clinicians can provide a more holistic and evidence-based approach to managing autoimmune neuritis, aiming to alleviate symptoms and improve patient outcomes.
References
1 Salathia S, Gigliobianco MR, Casadidio C, Di Martino P, Censi R. Hyaluronic Acid-Based Nanosystems for CD44 Mediated Anti-Inflammatory and Antinociceptive Activity. International journal of molecular sciences 2023. link 2 Fan L, Yu Z, Li J, Dang X, Wang K. Immunoregulation effects of bone marrow-derived mesenchymal stem cells in xenogeneic acellular nerve grafts transplant. Cellular and molecular neurobiology 2014. link 3 Hua S, Hermanussen S, Tang L, Monteith GR, Cabot PJ. The neural cell adhesion molecule antibody blocks cold water swim stress-induced analgesia and cell adhesion between lymphocytes and cultured dorsal root ganglion neurons. Anesthesia and analgesia 2006. link
3 papers cited of 4 indexed.